Daratumumab in combination with bortezomib plus dexamethasone or lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma: phase 3 CASTOR and POLLUX subgroup analyses in patients with early or late relapse after initial therapy

被引：0

作者：

Goldschmidt, H. ^{[1
,2
]}

Spencer, A. ^{[3
]}

Moreau, P. ^{[4
]}

Mateos, M. V. ^{[5
]}

Suzuki, K. ^{[6
]}

Levin, M. D. ^{[7
]}

Sonneveld, P. ^{[8
]}

Yoon, S. S. ^{[9
]}

Usmani, S. Z. ^{[10
]}

Weisel, K. ^{[11
]}

Reece, D. ^{[12
]}

Ahmadi, T. ^{[13
]}

Pei, H. ^{[14
]}

Mayo, W. G. ^{[15
]}

Gai, X. ^{[16
]}

Carey, J. ^{[17
]}

Carson, R. ^{[17
]}

Dimopoulos, M. A. ^{[18
]}

机构：

[1] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[2] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[3] Alfred Hlth Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia

[4] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[5] Univ Hosp Salamanca, IBSAL, Canc Res Ctr, IBMCC,USAL CSIC, Salamanca, Spain

[6] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[7] Albert Schweitzer Hosp, Dordrecht, Netherlands

[8] Erasmus MC Canc Inst, Rotterdam, Netherlands

[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[10] Mem Sloan Kettering Canc Ctr, New York, NY USA

[11] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[12] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[13] Genmab US Inc, Plainsboro, NJ USA

[14] LLC, Janssen Res & Dev, Titusville, NJ USA

[15] LLC, Janssen Res & Dev, Raritan, NJ USA

[16] LLC, Janssen Res & Dev, Beijing, Peoples R China

[17] LLC, Janssen Res & Dev, Spring House, PA USA

[18] Natl & Kapodistrian Univ Athens, Athens, GA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P427

引用

页码：142 / 142

页数：1

共 50 条

[1] Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.
Spencer, Andrew
Moreau, Philippe
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Suzuki, Kenshi
Levin, Mark-David
Sonneveld, Pieter
Yoon, Sung-Soo
Usmani, Saad Zafar
Weisel, Katja
Reece, Donna Ellen
Ahmadi, Tahamtan
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Carson, Robin L.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
Mateos, Maria-Victoria
Richardson, Paul
Weisel, Katja
Moreau, Philippe
San-Miguel, Jesus
Goldschmidt, Hartmut
Orlowski, Robert
Sonneveld, Pieter
Reece, Donna E.
Suzuki, Kenshi
Bahlis, Nizar
Yoon, Sung-Soo
Spencer, Andrew
Nooka, Ajay
Hungria, Vania
Plesner, Torben
Ben Yehuda, Dina
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Carson, Robin
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
[3] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[4] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Suzuki, Kenshi
Dimopoulos, Meletios A.
Takezako, Naoki
Okamoto, Shinichiro
Shinagawa, Atsushi
Matsumoto, Morio
Kosugi, Hiroshi
Yoon, Sung-Soo
Huang, Shang-Yi
Qin, Xiang
Qi, Ming
Iida, Shinsuke
BLOOD CANCER JOURNAL, 2018, 8
[5] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Kenshi Suzuki
Meletios A. Dimopoulos
Naoki Takezako
Shinichiro Okamoto
Atsushi Shinagawa
Morio Matsumoto
Hiroshi Kosugi
Sung-Soo Yoon
Shang-Yi Huang
Xiang Qin
Ming Qi
Shinsuke Iida
Blood Cancer Journal, 8
[6] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Spencer, Andrew
Lentzsch, Suzanne
Weisel, Katja
Avet-Loiseau, Herve
Mark, Tomer M.
Spicka, Ivan
Masszi, Tamas
Lauri, Birgitta
Levin, Mark-David
Bosi, Alberto
Hungria, Vania
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay K.
Quach, Hang
Lee, Cindy
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Scott, Emma C.
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Beksac, Meral
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Sonneveld, Pieter
Soong, David
Casneuf, Tineke
Chiu, Christopher
Amin, Himal
Qi, Ming
Thiyagarajah, Piruntha
Sasser, A. Kate
Schecter, Jordan M.
Mateos, Maria-Victoria
HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
[7] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Avet-Loiseau, Herve
Casneuf, Tineke
Chiu, Christopher
Laubach, Jacob P.
Lee, Je-Jung
Moreau, Philippe
Plesner, Torben
Nahi, Hareth
Khokhar, Nushmia Z.
Qi, Ming
Schecter, Jordan
Carlton, Victoria
Qin, Xiang
Liu, Kevin
Wu, Kaida
Zhuang, Sen H.
Ahmadi, Tahamtan
Sasser, A. Kate
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[8] Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Spencer, Andrew
Moreau, Philippe
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Suzuki, Kenshi
Levin, Mark-David
Sonneveld, Pieter
Orlowski, Robert Z.
Yoon, Sung-Soo
Usmani, Saad Z.
Weisel, Katja
Reece, Donna
Ahmadi, Tahamtan
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Bartlett, J. Blake
Carson, Robin
Dimopoulos, Meletios A.
BLOOD ADVANCES, 2024, 8 (02) : 388 - 398
[9] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
Palumbo, A.
Chanan-Khan, A.
Weisel, K.
Nooka, A. K.
Masszi, T.
Beksac, M.
Spicka, I.
Hungria, V.
Munder, M.
Mateos, M. V.
Mark, T.
Qi, M.
Schecter, J.
Amin, H.
Qin, X.
Deraedt, W.
Ahmadi, T.
Spencer, A.
Sonneveld, P.
HAEMATOLOGICA, 2016, 101 : 340 - 341
[10] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
van Beurden-Tan, C.
Forero, J.
Coggia, A.
Bustos Marquez, M. C.
VALUE IN HEALTH, 2019, 22 : S480 - S480

← 1 2 3 4 5 →